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Abstract
Introduction
• Lyme disease is caused by spirochetes called Borrelia 
burgdorferi sensu lato that is transmitted to humans by ticks.  
The transmission happens through injection of tick saliva 
during feeding.  Infection in humans activate innate and 
adaptive immune responses that kill spirochetes.  
• Virulence factors that can cause persistent infection including 
downregulation of immunogenic surface proteins, alteration of 
antigenic properties of lipoproteins and binding to components 
of extracellular matrix
• Horowitz (2013) described that Borrelia has 3 major forms: cell 
wall, cystic, and intracellular which can protect itself from the 
body’s immune system depending on the internal environment 
it’s in.   
• Bratton (2008) reported Lyme Borrelia spirochetes are 
susceptible to tetracyclines, penicillins, macrolides, and 2nd and 
3rd cephalosporins.  
• IDSA recommends treatment with antibiotics 14-21 days and 
ILADS recommends using treatment regimens of minimum of 
4-6 weeks. 
• Borgermans (2014) found when Lyme is treated early, the 
outcomes are good.  20% of people display recurrent symptoms 
after antibiotic treatment. 
• Cameron (2014) found that 34% of patients were ill an average 
of 6.2 years after standard antibiotic treatment.  A meta-analysis 
of 504 patients treated for Lyme disease found this group had 
more fatigue, musculoskeletal pain and neurocognitive 
difficulties. 
• IDSA and ILADS, have different sets of guidelines for treating 
Lyme disease.  IDSA does not recognize the efficiency of long-
term antibiotics.  ILADS recognizes that the standard course of 
antibiotics are needed but that additional longer treatment may 
be needed to further eliminate symptoms.  
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Discussion
• Both short term and long term treatment regiments can be 
beneficial for reducing the persistent symptoms of Lyme 
disease. 
• Short term course of antibiotics are beneficial if treatment is 
performed early enough in the course of the disease.  
• Patients with persistent symptoms, would benefit from long 
term antibiotic treatments to help with symptoms of fatigue, 
pain, cognition and function.  
• No one duration of antibiotic treatment has been demonstrated 
superior from the current research.    
• 25-34% of patients will have ongoing Lyme symptoms after 
initial course of antibiotic treatment.  
• All of the research found the use of a single antibiotic treatment 
regimen of either short term or long term had some benefit in 
symptoms.    
• More research is needed for the use of combined antibiotic 
treatments and durations.         
• Lyme disease is the most common tick borne illness in the 
United States with over 300,000 cases annually. 
• Two main organizations called the Infectious Disease Society of 
America and the International Lyme and Associated Diseases 
Society differ on their opinions in the treatment duration of 
Lyme disease. 
• A review of the literature explored studies that compared the 
effectiveness of short term versus long term antibiotics in the 
treatment of Lyme. Determining the most effective treatment 
method duration for reducing the long term risk of persistent 
symptoms of Lyme will be important for the improvement of the 
delivery of care for patients. 
• In patients diagnosed with Lyme Borrelia burgdorferi, is short 
versus long term antibiotics better for reducing persistent Lyme 
symptoms?
The search of the literature found the main points:  
• Stanek (2012) estimates it takes anywhere from 17-36 hours for 
Borrelia to be transferred. 
• Ixodes nymphs are most active from early summer to early 
autumn.  Adults will not become active until autumn.  Adults 
remain active through winter months except when temperature 
drop less than 37.4 degrees F. 
• Preboth (2001) found IDSA recommends antibiotic treatment 
for 10-21 days for erythema migrans rash. 
• Cameron (2014) found ILADS recommends a minimum of a 20 
day course of antibiotics for Ixodes tick bite.  When erythema 
migrans is present,  treatment with antibiotics for a minimum of 
4-6 weeks is recommended.   Patients with persistent symptoms 
are treated with additional 4-6 weeks of antibiotics.  
• Warshafsky (2010) found that those who received antibiotic 
prophylaxis by single dose or antibiotic <10 day duration, 
within 72 hours of Ixodes tick bite accompanied by erythema 
migrans as the presenting symptom were less likely to acquire 
Lyme disease than those given placebo with a RRR of 91%.   
• Kowalski (2010) reported patients with early localized or early 
disseminated Lyme disease treated for <10 days with antibiotics 
have long-term outcomes similar to those of patients treated 
with longer courses of antibiotics.  
• Fallon (2008) found that patients with Lyme encephalopathy 
treated with additional 10 weeks of IV ceftriaxone had greater 
improvement in cognition, physical functioning, pain and 
fatigue at 12 weeks after treatment, but at the 24th week 
improvement in cognition was not sustained.  The study did 
find clinical significance in the most severely affected patients 
on physical function and pain. 
• Delong (2012) found that when patients with confirmed Lyme 
disease received one standard course of antibiotic therapy for 21 
days, who continued to have symptoms within 6 months of 
disease and received an additional 4 week course of IV 
ceftriaxone were found to have improved function and pain 
levels.
• Krupp (2003) reported that when patients received 28 days of 
IV ceftriaxone, after being treated with the standard course of 
21 days of antibiotics, within 6 months of treatment they were 
found to have improvements in fatigue but not cognitive 
function (95% CI, P<.001). 
• Horowitz (2013) reports that 75% of patients with acute Lyme 
disease will have resolution of symptoms in < 2 months if all 3 
forms of Lyme Borrelia are treated with different regimens of 
antibiotics.  Close to 25% of patients may need a longer course 
>2 months of antibiotic treatment if symptoms persist.    
• Most clinicians in the United States use the IDSA guidelines for 
treatment of Lyme disease of 14-21 days.  
• Improvements are seen in the majority of patients when treated 
early.    
• Be aware of ongoing symptoms of Lyme disease which can 
include: fatigue, arthralgias, myalgias, headaches, sleep 
insomnia and numbness or tingling in the extremities.
• Testing for Lyme disease with the current diagnostic tests has 
low specificity and sensitivity.  A clinical diagnosis is usually 
needed.  
• Lyme disease treatments should be clinical and patient based. 
• Horowitz questionnaire is a great tool to use for initial screening 
to help with clinical diagnosis of Lyme disease.  
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